London, United Kingdom
Engitix Therapeutics, founded in 2016 and headquartered in the United Kingdom, is at the forefront of the Biotechnology, Health Care, and Life Sciences industries. The company aims to transform therapy development for chronic diseases through its pioneering extracellular matrix (ECM)-based discovery platform.
Engitix’s platform leverages human in vitro models to more accurately simulate the natural cell microenvironment. This innovative approach enhances the identification of new drug targets, elucidates mechanisms of action, and improves the prediction of therapeutic candidates' success rate, ultimately accelerating drug discovery and reducing late-stage clinical failures.
Having secured a substantial $54.00M Series A investment on January 19, 2022 from investors such as DOMPE and Netherton Investments, Engitix is well-positioned to further advance its ECM platform. Their work in fibrosis and solid tumors holds promise for developing unprecedented therapies to combat life-threatening diseases.
